SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Accounting Policies (Details) (USD $)	0 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Jan. 27, 2014	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Depreciation		$ 100,000	$ 200,000	$ 200,000	$ 300,000
Stock split, conversion ratio	0.0833
Common stock, par value (in dollars per share)		$ 0.01		$ 0.01		$ 0.01
Share-based compensation arrangement by share-based payment award, expiration period				10 years
Unvested stock options, unrecognized compensation expense weighted average recognition period				1 year 6 months
Stock-based compensation				637,000	162,000
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, stock options		1,400,000		1,400,000
Stock options, granted		15,499			159,375
Stock options, fair value assumptions, risk free interest rate		1.74%
Stock options, fair value assumptions, dividend yield		0.00%
Stock options, fair value assumptions, expected life		4 years 4 months 17 days
Stock options, fair value assumptions, historical volatility rate		83.00%
Common stock rights issued				115,065	691,656
Deferred revenue		1,212,000		1,212,000		1,088,000
Foreign currency translation adjustment, net of tax		22,000	0	34,000	(173,000)	(45,000)
Foreign currency transaction gain (loss), realized				(100,000)	100,000
Options, warrants and conversion rights, common stock callable and antidilutive (in shares)				5,510,255	3,334,055
CEO
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, unvested options, vesting period				3 years
Common stock rights issued				83,333
Share-based compensation arrangement by share-based payment award, fair value assumptions, exercise price		$ 4.32		$ 4.32
CFO
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock rights issued				55,000
Pharmacogenomic services
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferred revenue		300,000		300,000		200,000
Diagnostic tools
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferred revenue		900,000		900,000		900,000
Additional Paid-in Capital (1) | Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation				600,000	200,000
Accumulated Other Comprehensive Income
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Foreign currency translation adjustment, net of tax				$ 34,000	$ (200,000)	$ (45,000)
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, unvested options, vesting period				1 year
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, unvested options, vesting period				3 years